Burzynski Research Institute Competitors and Similar CompaniesClear all
Burzynski Research Institute's competitors and similar companies include EUSA Pharma, PDL BioPharma, X4 Pharmaceuticals and OSE Immunotherapeutics.
 Burzynski Research Institute Burzynski Research Institute is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. |  PDL BioPharma PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities. |  X4 Pharmaceuticals X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services. |  OSE Immunotherapeutics OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. | ||
Founding Date | Founding Date 1984 | Founding Date 2015 | Founding Date 1986 | Founding Date 2010 | Founding Date 2012 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Houston, US HQ Stafford, US | Locations Hemel Hempstead, GB HQ | Locations Incline Village, US HQ | Locations Boston, US HQ Wien, AT | Locations Nantes, FR HQ Paris, FR |
Employees | Employees N/A | Employees 965% decrease | Employees 10521% increase | Employees 1005% increase | Employees 52 |
Valuation ($) | Valuation ($) 4.7 m | Valuation ($) N/A | Valuation ($) 282.1 m | Valuation ($) 83.9 m | Valuation ($) 239 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $54.8m (FY, 2019) | Revenue (est.) $6.5m (FY, 2025) | Revenue (est.) €69.9m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $53.6m (FY, 2019) | Cost of goods $5.8m (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $1.1m (FY, 2019) | Gross profit $743k (FY, 2025) | Gross profit €83.4m (FY, 2024) |
Net income | Net income ($1.4m) (FY, 2025) | Net income N/A | Net income ($70.7m) (FY, 2019) | Net income N/A | Net income €37.4m (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 54.2m | Total funding raised N/A | Total funding raised $ 64.5m | Total funding raised $ 10.3m |
For sources of this data, please see the company profile
View Company Profiles
EUSA Pharma
HQ
Hemel Hempstead, GB
Employees
96↓ 5% decrease
EUSA Pharma is a biopharmaceutical company focused on oncology and rare diseases.
View companyPDL BioPharma
HQ
Incline Village, US
Employees
105↑ 21% increase
PDL BioPharma, Inc. engages in intellectual property asset management, and patent portfolio and related assets investment activities.
View companyX4 Pharmaceuticals
HQ
Boston, US
Employees
100↑ 5% increase
X4 Pharmaceuticals (formerly known as Arsanis) is a biopharmaceutical company that provides drug development services.
View companyOSE Immunotherapeutics
HQ
Nantes, FR
Employees
52
OSE Immunotherapeutics is a biotechnology company that focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases.
View company